GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Molecular Partners AG (XSWX:MOLN) » Definitions » Intrinsic Value: Projected FCF

Molecular Partners AG (XSWX:MOLN) Intrinsic Value: Projected FCF : CHF2.68 (As of May. 01, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Molecular Partners AG Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-01), Molecular Partners AG's Intrinsic Value: Projected FCF is CHF2.68. The stock price of Molecular Partners AG is CHF3.29. Therefore, Molecular Partners AG's Price-to-Intrinsic-Value-Projected-FCF of today is 1.2.

The historical rank and industry rank for Molecular Partners AG's Intrinsic Value: Projected FCF or its related term are showing as below:

XSWX:MOLN' s Price-to-Projected-FCF Range Over the Past 10 Years
Min: 1.19   Med: 1.28   Max: 1.28
Current: 1.23

During the past 11 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Molecular Partners AG was 1.28. The lowest was 1.19. And the median was 1.28.

XSWX:MOLN's Price-to-Projected-FCF is ranked better than
77.07% of 205 companies
in the Biotechnology industry
Industry Median: 2.36 vs XSWX:MOLN: 1.23

Molecular Partners AG Intrinsic Value: Projected FCF Historical Data

The historical data trend for Molecular Partners AG's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Molecular Partners AG Intrinsic Value: Projected FCF Chart

Molecular Partners AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only -5.93 -4.23 -6.94 - 2.68

Molecular Partners AG Quarterly Data
Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 5.84 4.77 3.92 2.68

Competitive Comparison of Molecular Partners AG's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Molecular Partners AG's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Molecular Partners AG's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Molecular Partners AG's Price-to-Projected-FCF falls into.



Molecular Partners AG Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Molecular Partners AG's Free Cash Flow(6 year avg) = CHF-5.59.

Molecular Partners AG's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-5.58784+176.429*0.8)/32.855
=2.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG  (XSWX:MOLN) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Molecular Partners AG's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=3.29/2.6767614834273
=1.23

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Molecular Partners AG Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Molecular Partners AG's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Molecular Partners AG (XSWX:MOLN) Business Description

Traded in Other Exchanges
Address
Wagistrasse 14, Schlieren, Zurich, CHE, 8952
Molecular Partners AG is a clinical stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.

Molecular Partners AG (XSWX:MOLN) Headlines

From GuruFocus

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

By Stock market mentor Stock market mentor 01-08-2023